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Abstract  
Tumor-expressed ICAM-1 interaction with LFA-1 on naïve tumor-specific CD8+ T 
cells not only stabilizes adhesion, but in the absence of classical B7-mediated 
costimulation, is able to provide potent alternative costimulatory signaling resulting in 
the production of antitumor cytotoxic T lymphocyte (CTL) responses. This study 
shows that overproduction of prostaglandin (PG) E2 by metastatic murine renal 
carcinoma (Renca) cells inhibited direct priming of tumor-specific CTL responses in 
vivo by preventing the IFNγ-dependent upregulation of ICAM-1 that is vital during the 
initial priming of naïve CD8+ T cells.  The addition of exogenous IFNγ during naïve 
CD8+ T-cell priming abrogated PGE2-mediated suppression, and overexpression of 
ICAM-1 by tumor cells restored IFNγ production and proliferation amongst PGE2-
treated tumor-specific CD8+ T cells; preventing tumor growth in vivo.  These findings 
suggest that novel anticancer immunotherapies, which increase expression of ICAM-
1 on tumor cells, could help alleviate PGE2-mediated immune-suppression of 
antitumor CTL responses.  
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Introduction  
Strengthening tumor-specific CD8+ cytotoxic T lymphocyte (CTL) responses is one of 
the most promising recent strategies in cancer therapy. However, antitumor CTL 
activity is widely suppressed within the tumor microenvironment. Understanding 
mechanisms of suppression and ways to overcome them, are key challenges in 
cancer immunotherapy (1-6).  
 
Overproduction of PGE2 by tumor cells as a result of overexpression of 
cyclooxygenase (COX)-2 (7-11), suppresses antitumor immune responses. Studies 
have shown that PGE2 suppresses both innate and adaptive immune responses. It 
alters NK cell effector function by decreasing TNF and IFNγ production (12), and 
reduces phagocytosis by macrophages (13). PGE2 can also disrupt antigen 
presentation by dendritic cells (DC), either by inhibiting maturation, which alters the 
profile of cytokine production and reduces secretion IL2 and IL12, or by inducing 
exhaustion, which prevents the induction of CTL, type 1 helper T (Th1) cells, and 
natural killer (NK) cells in favor of Th2 responses (14-16). 
 
In earlier studies from our laboratory, murine renal cell carcinoma (Renca) cells that 
expressed the hemagglutinin (HA) protein from influenza virus A/PR/8/H1N1 (PR8) 
as a tumor-specific neoantigen (RencaHA cells) were generated. We transfected 
them to overexpress COX-2 (RencaHA/T3 cells), which resulted in elevated PGE2 
production.  Overexpression of COX-2 by RencaHA/T3 cells induced metastasis to 
the tumor draining lymph nodes (TDLN). Yet despite tumor growth, when CD8+ T 
cells transgenic for the CLR TCR (a H-2Kd/HA–specific T cell receptor) were 
adoptively transferred into RencaHA/T3 tumor-bearing mice CLR T cells in the TDLN 
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remained naïve (15)., The lack of CL4 T cell proliferation and CTL effector function 
was dependent on COX-2 overexpression by RencaHA/T3. Treatment of 
RencaHA/T3 tumor-bearing mice with the selective COX-2 inhibitor NS-398 restored 
both proliferation and CTL effector function to CL4 T cells within the TDLN to the 
same level found within the TDLN of COX-2 negative RencaHA tumor-bearing mice.  
 
The immunosuppressive effects of PGE2 are known to be associated with increased 
intracellular cyclic adenosine monophosphate (cAMP) (17)(13), which modulates the 
effector function of T cells and inhibits the stabilization of the immunological synapse 
formed through LFA-1–ICAM-1 interactions (17-20), which influences subsequent 
IFNγ-dependent T-cell proliferation.  Several studies have shown that T-cell surface 
expression of ICAM-1 by tumor cells can be induced by IFNγ derived from CD8+ T 
cells during productive activation (21, 22). Therefore, we hypothesized that 
suppression of IFNγ production by CL4 CTL interacting with metastatic RencaHA/T3 
in the presence of high concentrations of PGE2, would inhibit upregulation of ICAM-1 
on tumor cells, which is required to drive proliferation and differentiation of tumor-
specific CTL responses. 
 
In this report we demonstrate that the concentration of PGE2 during CD8+ T-
cell/tumor cell interactions plays an essential role in determining the outcome of the 
response; shifting from productive activation of CTL at low concentrations, towards 
antigen-specific tolerance induction at high concentrations.  We show that 
exogenous PGE2 prevented the direct priming of CL4 CTL responses in vitro by  
suppressing IFNγ production by CL4 T cells when they initially interacted with 
RencaHA tumor cells, a critical event for proper priming.  We also show that 
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suppression by PGE2 was temporary and could be mitigated by increasing cell-
surface expression of ICAM-1 by tumor cells. ICAM-1 expression not only drove 
tumor-specific CD8+ T-cell proliferation, but also limited tumor growth in vivo. 
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Materials and Methods  
Mice. Thy1.1+/+ CL4 TCR–transgenic BALB/c mice (6 to 8-wk-old) (23), and Thy1.2+/+ 
BALB/c mice were maintained under specific pathogen–free conditions at the 
University of Bristol Animal Services Unit. Some BALB/c mice were injected 
subcutaneously (s.c.) with 1×106 Renca tumor cells and tumor growth was assessed 
as previously described (15, 21). 
 
Cell lines.  COX-2-overexpressing RencaHA/T3 cells (9, 21, 24), were transfected 
with 1.5 µg of ICAM-1 expressing pIREShyg plasmid (a kind gift from Prof. Adrian 
Whitehouse at Leeds University), to generate RencaHA/T3/ICAM-1.  Renca cells 
were grown in a complete medium (RPMI (1640); Sigma-Aldrich, Poole, UK) 
supplemented with 10% vol./vol. fetal calf serum (FCS, Invitrogen, Paisley, U.K.); 2 
mM L-glutamine (Invitrogen); penicillin/streptomycin (50 U/ml, Invitrogen), 5 × 10-5 M 
2-mercapto-ethanol (Invitrogen). Medium was further supplemented with; geneticin 
(100 µg/ ml, Invitrogen) for RencaHA cells, plus puromycin (1 µg/ml; Biomatik, 
Wilmington, USA) for RencaHA/T3, plus  hygromycin B (250 µg/ml, Invitrogen) for 
RencaHA/T3/ICAM-1. Expression of HA, COX-2, ICAM-1 and concentrations of 
PGE2 were routinely monitored during the study. 
 
Enrichment of Kd/HA-specific CL4 CD8+ T cells.  Single cell suspensions from 
peripheral lymph nodes and spleen of Thy1.1+ CL4 TCR–transgenic mice were 
enriched for CD8+ T cells using anti-CD8 MACS midiMACS (Miltenyi Biotec, Bisley, 
UK) (25).  
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CFSE labeling.  MACS-purified naïve CL4 CD8+ T cells were pelleted, resuspended 
in 50 × 106 cells/ml in PBS and mixed with 5 µM CFSE (BioLegend, San Diego, 
USA), for 15 minutes at 37oC in the dark, and then washed with 45ml complete 
medium. 
  
Priming of naïve CL4 CD8+ T cells by tumor cells.  Naïve CFSE-labeled CL4 
CD8+ T cells were cultured with irradiated tumor cells at a ratio of 1:1 in the presence 
of different concentrations of PGE2 (Sigma-Aldrich).  In some experiments, RencaHA 
cells were treated overnight with different concentrations of PGE2, before being 
washed and used for priming naïve CL4 cells. In other experiments, CL4 cultures 
were treated with recombinant (r)IFNγ (Peprotec), or cultured in plates coated with 
rICAM-1 (Sion Biological Inc.), overnight before adding RencaHA and CL4 cells.  
 
Priming of naïve CL4 CD8+ T cells with plate-bound monoclonal antibodies 
(mAb). Tissue culture plates were coated with 10 mg/ml anti-CD3 (eBioscience, 
Hatfield, U.K.) at 4°C. Control wells contained PBS only. MACS-purified, CFSE-
labeled naïve CL4 cells (5 × 104 – 25 × 104) were cultured, with or without CD28 
mAbs (5 µg/ml, eBioScience), for 48 at 37°C with 5% vol./vol. CO2. CL4 cells were 
then collected and stained with various other mAbs. In other experiments, plates 
were coated with CD3 mAbs and/or rICAM-1 before the addition of naïve CL4 cells. 
For the secondary activation of CL4 CD8+ T cells pre-activated by tumor, CFSE-
labeled CL4 cells (1 x 106) recovered from primary cultures were restimulated with 1 
x 105 freshly irradiated tumor cells in 24 well plates in the presence or absence of 
10–6 M PGE2 for 37°C in 5% vol./vol. CO2.  
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cAMP ELISA. CL4 cells were treated with 1 mM of 3-Isobutyl-1-methylxanthine 
(IBMX), an inhibitor of cAMP phosphodiesterases, for 1 h at 37°C followed by 10–6 M 
PGE2 for 10mins, then lysed at 4°C. ELISA was performed using the BIOMOLFormat 
A Cyclic AMP plus EIA kit (Exeter, UK), according to the manufacturer’s instructions. 
Plates were read at 405 nm with a 590 nm reference using a 3550 microplate reader 
(BioRad, CA, USA). Data were analyzed using Microplate Manager® 4.0 (BioRad) 
and the graphs plotted using Prism 4.03 software (GraphPad).  
 
Flow cytometry.  MACS-purified CL4 cells were restimulated in vitro for 4 h in the 
presence of 1µg/ml of both KdHA peptide and Golgiplug (BD Bioscience San Diego, 
USA), stained with Zombie AquaTM to exclude dead cells (Biolegend), and various 
fluorescently-conjugated mAbs against surface markers; CD69, CD62L and CD44 
(BioLegend). CL4 cells were then permeabilized using BD Perm/fix kit (BD 
Bioscience) according to manufacturer’s instructions and stained with anti-IFNγ 
mAbs (Biolegend). Cells were analyzed using an LSRII or FACSCalibur flow-
cytometer with DiVa or CellQuest software respectively (BD Cytometry Systems 
Oxford, UK).  
 
Results  
To determine if PGE2 affected the direct priming of naive tumor-specific CD8+ T cells 
by tumor cells, CFSE-labeled naïve Kd/HA-specific CL4 CD8+ T cells were cocultured 
with RencaHA cells for 72 h in the presence of increasing concentrations of PGE2 
([RencaHA+CL4]+PGE2; Fig, 1A, top). Nontransfected (HA-negative), RencaNT cells 
were used as a negative control. After coculture, CL4 cells were isolated and 
analyzed for proliferation using standard 3H-thymidine incorporation (Fig. 1, left), as 
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well as for intracellular IFNγ expression using flow cytometric analyses (Fig. 1,  
right).  In the absence of PGE2, CL4 cells proliferated and produced IFNγ production 
compared with CL4 cells cocultured with RencaNT cells.  However, in the presence 
of 10-6-10-10 M  PGE2, proliferation and IFNγ production by CL4 cells was 
significantly reduced when compared with untreated cultures and at 10-11M PGE2 
CL4 proliferation increased in response to RencaHA cells; although this was not 
significant. Importantly, when RencaNT cells were cultured with CL4 cells in the 
presence of PGE2, no significant change was observed amongst CL4 cells and they 
maintained their naïve phenotype (data not shown). Correlating with reduced 
proliferation, amongst CL4 cells cultured with RencaHA cells in the presence of the 
highest concentrations of PGE2, (10-6 and 10-7 M), IFNγexpression was significantly 
reduced compared with PGE2-untreated cultures. However, when CL4 cells were 
cultured with RencaHA at lower concentrations of PGE2, (10-10 M), both proliferation 
and IFNγ expression increased compared with untreated cultures.   
 
The regulation of naïve CD8+ T-cell responses by PGE2 could be direct, or indirect,, 
by conditioning the tumor cells. To determine if the effect is indirect, RencaHA cells 
were pretreated with various concentrations of PGE2 (Fig. 1A, bottom).  However, 
prior to coculture, RencaHA cells were washed to remove any excess PGE2 
([RenaHA+PGE2]+CL4).  After 72 h CL4 cells were isolated and analyzed for 
proliferation (left panel) and intracellular IFNγ expression by flow cytometry (right 
panel). The data show that, compared with PGE2-untreated cultures, pretreatment of 
RencaHA cells with PGE2 did not result in a significant reduction in CL4 proliferation 
even at the highest concentration of PGE2. Furthermore, IFNγ expression was also 
unaffected by pretreatment of RencaHA cells with PGE2, with a slight increase in 
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expression being significant only at 10-8 M. Together these data suggest that high 
concentrations of PGE2 suppresses proliferation and CTL effector function in vitro by 
acting directly upon CL4 cells.   
 
The direct effect of high concentrations of PGE2 on CL4 cell priming was further 
examined by culturing CFSE-labeled CL4 cells in the presence of immobilized anti-
CD3 and anti-CD28 mAb with or without 10-6 M PGE2 (Fig. 1B). Although untreated 
CL4 T cells proliferated and elaborated IFNγ, the presence of high concentrations of 
PGE2 resulted in a reduction in proliferation, with many more undivided CFSE-high 
cells, and a significant decrease in IFNγ expression. Thus, the inhibitory effects of 
PGE2 are most likely mediated through direct action on naïve CL4 cells.  
 
PGE2 inhibits reactivation of CD8+ T cells 
To determine whether or not inhibition of CL4 T-cell proliferation and IFNγ production 
by high concentrations of PGE2 is permanent, naïve CFSE-labeled CL4 cells were 
first primed in vitro with RencaHA cells in the presence or absence of PGE2. After 48 
h, CL4 cells were isolated and washed to remove excess PGE2, before undergoing a 
secondary culture for a further 72 h with fresh RencaHA cells in the presence or 
absence of more PGE2.  CL4 cells cultured in the presence of nontransfected, HA 
negative RencaNT cells were used as a control.   
 
The data show that CL4 cells from primary cocultures without PGE2 proliferated and 
produced IFNγ (Fig. 2A; top row), and following secondary coculture with fresh 
RencaHA cells alone in the absence of PGE2, resulted in further proliferation with 
over than 40% of cells being IFNγ+. However, when PGE2 was added to these 
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secondary cocultures, proliferation was less, with fewer than 10% of cells being  
IFNγ+.  Critically, when PGE2-treated CL4 cells from primary cocultures underwent a 
secondary coculture with fresh RencaHA cells in the absence of PGE2, nearly half of 
the CL4 cells had proliferated, and one-tenth of divided cells were IFNγ+, as 
compared with CL4 cells to which PGE2 was also added in the secondary coculture 
(Fig. 2A; bottom row).  Therefore, suppression by PGE2 was reversible, and 
withdrawing PGE2 from the environment could restore CL4 proliferation and CTL 
effector function.    
 
The inhibition of effector function among PGE2-treated CD8+ T cells is associated 
with increased cAMP, which inhibits IFNγ production and the acquisition of CTL 
effector function (17-20, 26).  To establish whether or not PGE2 suppresses naïve 
CL4 cells in a cAMP-dependent manner, naïve PGE2-treated CL4 cells were lysed, 
and intracellular cAMP concentrations were measured using an ELISA. Following 
PGE2 treatment, cAMP expression amongst CL4 cells rose by around threefold 
compared to untreated CL4 cells (Fig. 2B).  
 
IFNγ reverses inhibition of CTL function  
We previously demonstrated that IFNγ treatment of RencaHA cells increased 
antitumor CTL responses by enhancing MHC class I (H-2Kd) expression by tumor 
cell (21). To determine whether or not the presence of exogenous IFNγ could directly 
influence CL4 T-cell responses in the presence of PGE2, CFSE-labeled naïve CL4 
cells were cocultured with RencaHA cells in the presence or absence of PGE2 and 
rIFNγ and proliferation, (determined by reductions in CFSE), and IFNγ production, 
were assessed by flow cytometry. The proliferation and IFNγ production of CL4 T 
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cells were inhibited by PGE2.(Fig. 3A). However, addition of rIFNγ to these PGE2-
treated RencaHA+CL4 cocultures counteracted the suppression of proliferation and 
IFNγ production. Addition of rIFNγ also resulted in increased expression of the early 
activation marker CD69 on proliferating CL4 cells, indicating that the presence of 
rIFNγ, during the initial priming of naïve CL4 cells, is essential to reverse the 
suppressive effects of PGE2 (Fig. 3B). Treatment of RencaNT+CL4 cocultures with 
rIFNγ did not result any nonspecific increase in proliferation amongst CL4 cells (Fig. 
3A and B: top rows).  
 
As IFNγ receptors are expressed on a variety of cell types including naïve CD8+ T 
cells and tumor cells (27, 28), it is possible that in the RencaHA+CL4 cocultures, 
IFNγ may be acting on either or both cell types.  To address this issue, naïve CFSE-
labeled CL4 cells were primed with mAb to CD3 and CD28 in the presence or 
absence of PGE2 with or without rIFNγ. As anticipated control mAb-primed CL4 cells 
elaborated IFNγ after 72 h, which was further enhanced by the addition of rIFNγ (Fig. 
3C). However, although after PGE2 treatment, IFNγ production by CL4 cells primed 
with mAbs to CD3 and CD8 was inhibited, addition of rIFNγ did not restore IFNγ 
production by CL4 cells. Therefore, these data clearly show that reversal of the 
PGE2-mediated suppression of CTL effector function by IFNγ can only occur in the 
presence of Renca-HA cells.   
 
To test whether or not rIFNγ counteracts PGE2-mediated suppression by acting 
directly on RencaHA cells, cocultures were set up in which RencaHA cells were 
treated with rIFNγ at different time points in the presence of PGE2 (Fig. 4). Addition 
of 10 ng/ml of rIFNγ to RencaHA+CL4 cocultures at 0 and 20 h resulted in an 
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increase in proliferation, as both CFSE and IFNγ were reduced (Fig. 4; middle two 
rows). However, addition of rIFNγ to the cocultures after 40 h of exposure to PGE2 
did not enhance IFNγ production by CL4 cells (Fig. 4; bottom row). This suggests 
that the reversal of PGE2-mediated suppression by rIFNγ can occur in the very early 
stages of CL4 T-cell priming.  
 
ICAM-1–LFA-1 interactions abrogate inhibition in vitro 
Not only is ICAM-1 interaction with T cell–expressed LFA-1 crucial for the homotypic 
T-cell aggregation that is required for T-cell communication and exchanging 
information (29),  but the LFA-1–ICAM-1 interaction can transduce downstream 
costimulatory signals and drive T-cell proliferation (6, 27). We have shown that the 
cell-surface expression of ICAM-1 by RencaHA cells is crucial for direct priming of 
naïve CL4 T cells. Moreover, we showed that upregulation of ICAM-1 expression is 
induced by IFNγ derived from CL4 cells during their early activation by RencaHA 
cells. This reinforces further proliferation and the induction of CTL effector function 
(21, 22). Based upon these findings, we wished to compare classical anti-CD28 
costimulation, with alternative ICAM-1-mediated costimulation through LFA-1 Fig. 
5A). In the presence of rICAM-1, proliferation of naive CL4 T cells was significantly 
greater compared with the proliferation in the presence of anti-CD28 mAbs. Whereas 
some CL4 cells proliferated in response to CD3 mAb alone, rICAM-1 alone did not 
induce any proliferation (Fig. 5A).  These results indicated that ICAM-1 acts as a 
highly potent alternative costimulatory molecule to drive naïve CL4 T-cell 
proliferation.  
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It is known that following priming, T cells decrease surface expression of CD62L, 
and increase CD44 expression, enabling extravasation through blood vessels into 
inflamed tissues and the formation of effector memory T (Tem) cells (28). To test 
whether or not classical (CD3  mAb + CD28 mAb) or alternative (CD3 mAb + rICAM-
1) priming of naïve CL4 cells in vitro gave rise to Tem cells, CFSE-labeled naïve CL4 
cells were primed accordingly and the expression of CD62L, CD44, and IFNγ was 
assessed by flow cytometry.  Treatment of CFSE-labeled CL4 cells with anti-CD3 + 
rICAM-1 consistently produced more IFNγ-expesssing cells that divided two or more 
times, than when CL4 cells were primed with anti-CD3 + anti-CD28, (Fig. 5B),. 
Therefore, the induction of CTL effector function is at least comparable. Given the 
high expression of CD44 and low expression of CD62L under both conditions, the 
cells are Tem CTL (Fig. 5B).   
 
Our previous studies showed that, although low expression of ICAM-1 by RencaHA 
cells is sufficient to prime naïve CL4 cells (21), PGE2 has the ability to prevent 
priming of CL4 cells in vitro and in vivo (15). Therefore, we wished to compare the 
effect of PGE2 on classical (CD3 mAb + CD28 mAb), with alternative (CD3 mAb + 
rICAM-1) priming of CL4 cells in vitro. Furthermore, we also wished to determine 
whether or not increasing ICAM-1–mediated costimulation, by the addition of rICAM-
1, could counteract PGE2-mediated inhibition of naïve CL4 T-cell priming.   
 
Addition of exogenous PGE2 has a greater inhibitory effect upon classical CD28-
mediated costimulation compared with alternative ICAM-1-LFA-1 costimulation (Fig. 
6A). When CL4 cells were cocultured with RencaHA cells, addition of PGE2 resulted 
reduced CL4 proliferation by about two-thirds.  However, in the presence of rICAM-1 
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CL4 proliferation, in response to coculture with RencaHA cells, was unaffected by 
PGE2 (Fig. 6B). Thus, although PGE2 has a greater inhibitory effect upon ‘classical’ 
costimulation compared with ‘alternative’ costimulation pathway, suppression is 
significantly abrogated by the addition of rICAM-1.   
 
Countering PGE2 inhibition, with overexpressed ICAM-1.   
It is evident that IFNγ exerts its antitumor effects by directly (27, 30) enhancing 
immunogenicity through elevated ICAM-1 expression (10, 31). To determine whether 
or not upregulation of ICAM-1 is instrumental in abrogating PGE2-mediated 
suppression, COX-2-overexpressing RencaHA/T3 cells (15) were further transfected 
with a cDNA plasmid expressing full-length murine ICAM-1. The resulting 
RencaHA/T3/ICAM-1 cell line expressed much more ICAM-1 compared with 
conventional RencaHA/T3 cells, which increased further after treatment with rIFNγ 
(Fig, 7A). Despite having equivalent amounts of HA protein and PGE2 production 
(data not shown), overexpression of ICAM-1 by RencaHA/T3/ICAM-1 cells increased 
proliferation of naïve CL4 cells in vitro compared with RencaHA/T3 cells (Fig. 7B). 
Whereas s.c. injection of RencaHA/T3 cells into BALB/c mice resulted in the 
formation of solid tumors after 2 weeks, s.c. injection of RencaHA/T3/ICAM-1 cells 
did not result in tumor growth (Fig. 7C&D). Together, these data clearly show that 
overexpression of ICAM-1 can counteract PGE2-mediated immunosuppression; 
restoring CTL effector function and profoundly preventing tumor growth in vivo. 
 
16 
 
Discussion  
Overexpression of COX-2 by RencaHA/T3 cells not only results in abortive activation 
of CL4 CD8+ T cells in the TDLN of RencaHA/T3 tumor-bearing mice, but also 
facilitates metastasis of RencaHA/T3 cells to the TDLN (15).  However, whilst 
metastases of RencaHA/T3 cells to the TDLN would allow direct priming of naïve 
CL4 cells, overproduction of PGE2 prevented the induction of antitumor CTL 
responses in these mice (32). The experiments described in this report set out to 
determine the mechanisms of PGE2-mediated immunosuppression.  
 
PGE2 exhibits various and sometimes opposing effects on the immune responses. 
For example, not only does PGE2 stimulate activation of mast cells (33, 34), it also 
inhibits cytokine release by macrophages (35). We have shown that the 
concentration of PGE2 is a major factor in determining its overall affect upon CD8+ T-
cells responses. At physiological concentrations of ≤ 20 ng/ml, produced by 
constitutive expression of COX-1 (36), PGE2 is able to enhance productive activation 
of CL4 cells. However, at high concentrations found in COX-2 overexpressing tumor 
micro-environments in vivo (37), PGE2 prevents proliferation and IFNγ production 
CL4 cells in response to RencaHA cells.  We show that PGE2 mediates its effects 
through direct action on CL4 cells. In the absence of RencaHA cells, proliferation 
and IFNγ production by PGE2-treated CL4 cells primed by anti-CD3+anti-CD28 mAb 
was also reduced, and pretreatment of RencaHA cells with PGE2 did not reduce 
proliferation or IFNγ production by CL4 cells.   
 
The fact that the PGE2-mediated suppression of CL4 cell responsiveness could not 
be reversed by the addition of IL2 (Ahmadi and Morgan unpublished data) suggests 
ICAM-1 
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that PGE2 does not induce a state of functional unresponsiveness due to anergy.  
Our findings correlate with other data showing that PGE2 directly inhibits CTL  
function such as IFNγ production (20). However importantly, PGE2-mediated 
suppression of CL4 cells is reversible, as secondary re-stimulation of PGE2-
conditioned CL4 cells, with RencaHA cells in the absence of PGE2, restored 
proliferation and IFNγ production. Furthermore, irrespective of the primary culture 
conditions, the presence of PGE2 in the secondary cultures renders CL4 cells 
refractory to proliferation and IFNγ production.   
 
Consistent with the inhibition of CL4 CTL responses was an observed increase in 
intracellular cAMP following treatment with PGE2. Increased cAMP inhibits IFNγ 
production by T cells as well as inhibit stabilization of the interaction between LFA-1 
and ICAM-1 (17, 18) thus preventing T-cell activation due to the inability of the T 
cells and APCs to form a stable a synapse (18, 19). Yet, we showed that CL4 cells 
increased cell-surface expression of the early activation marker CD69, possibly as a 
result of cognate TCR signaling (38). We suggest that, although some initial cognate 
interactions may occur that result in the upregulation of CD69, these interactions are 
not sustained sufficiently enough to trigger IFNγ production to promote further 
interactions.  Our finding that rIFNγ reversed  PGE2-mediated suppression of naïve 
CL4 priming by directly increasing the immunogenicity of tumor cells correlates with 
other studies that suggest that IFNγ enhances antigen presentation by tumor cells 
through increased MHC class I expression (21, 22). 
 
Previously we showed that in the absence of classical CD28-mediated costimulation, 
the interaction of LFA-1 with ICAM-1 provides sufficient costimulatory signals to 
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prime naïve CD8+ T cells and induce CTL function (8, 10). We now show that 
costimulation provided through LFA-1 is more potent than costimulation through 
CD28, which may arise from that fact that the type and quantity of the signals 
induced within the T cell by these two costimulatory receptors are distinct from each 
other (29).  
 
In the presence of rICAM-1 cultures, CL4 cells produced more IFNγ and were 
CD44high and CD62Llow, facilitating T-cell migration from LN to the site of 
inflammation, a typically Tem CTL phenotype (30). Such differences were also 
observed when priming naïve CL4 cells with RencaHA tumor cells, in which 
costimulation occurs solely through ICAM-1-LFA-1 interaction. Blocking LFA-1 or 
ICAM-1 causes a reduction in CTL production of IFNγ and lysis (1, 2); therefore 
enhancing tumor invasion and metastasis. In addition, studies have shown in breast 
cancer that silencing of the ICAM-1 gene by siRNA decreased tumorigenicity in vitro 
(39).   
 
We showed that exposure to PGE2 during priming with both classical and alternative 
costimulation pathways gave rise to a reduction in CL4 proliferation and IFNγ 
production. However, PGE2-mediated suppression of priming with classical 
costimulation was greater than with alternative rICAM-1-mediated costimulation. In 
the presence of PGE2, addition of rICAM-1 together with RencaHA-expressed ICAM-
1 restored CL4 proliferation. Thus, in the presence of PGE2, LFA-1–ICAM-1 
signaling is essential to fully initiate CL4 T-cell priming, presumably due to the 
stabilizing effect of rICAM-1 on T-cell / tumor cell interactions,,increasing TCR 
signaling.  
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Increased expression of ICAM-1 among melanoma cells gives rise to an increase in 
the lysis-susceptibility of melanoma cells by lymphokine-activated killer cells (LAKs) 
(40). Other studies also showed that transfecting gastric cancer cells with ICAM-1 
causes significant increases in both adhesion to PBMC and subsequent lysis (41). 
Induction of ICAM-1 by artificial transcription factors results in decreased growth of 
ovarian cancer cells (42). Studies in mice show that siRNA-mediated silencing of 
hepatic ICAM-1 in vivo prior to injecting C26 murine colon carcinoma cells alters the 
liver microenvironment. In ICAM-1-/- mice, reduced numbers of C26 cancer cells 
were obtained from the liver as well as myeloid suppressor cells, and the numbers of 
TILs were increased compared with controls (43). In our study we found that 
overexpression of ICAM-1 in RencaHA/T3 cells restored their ability to induce CL4 
cell proliferation in vitro, despite the presence of PGE2. However, although these 
RencaHA/ T3/ICAM-1 cells express abundant ICAM-1 post transfection, treatment 
with exogenous IFNγ was could further increase ICAM-1 expression. Unlike 
conventional RencaHA/T3 cells, RencaHA/T3/ICAM-1 cells did not form tumors in 
BALB/c mice, suggesting that potent antitumor CTL had been primed which 
eradicated the tumors. 
 
Based upon our findings, we propose the following model to explain the role of 
alternative LFA-1–ICAM-1 costimulatory interactions in restoring CTL function in the 
presence of PGE2 (Supplementary Fig. S1).  In the steady state, naïve CL4 T cells 
express LFA-1 with low affinity for ICAM-1, and although coculture of naïve CL4 cells 
with RencaHA cells enables CL4 TCR interactions with H-2Kd/HA peptide 
complexes, this interaction is transient and may be terminated if a synapse does not 
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form between the interacting cells. However, this initial contact is sufficient to 
stimulate Ca2+ influx inside CL4 cell, which provides the necessary stimuli to 
increase the affinity of LFA-1 for ICAM-1 (Supplementary Fig. S1A). When 
expression of ICAM-1 on RencaHA cells is too low to maintain a stabilized 
interaction between CL4 cells and RencaHA cells (Supplementary Fig. S1B), 
increased cAMP levels within CL4 cells will interfere with Ca2+ influx, resulting in a 
reduction in the affinity of LFA-1 for ICAM-1. Eventually, interactions between the 
CL4 and RencaHA cells are terminated and they disassociate without any CL4 
proliferation and/or IFNγ production.  However, production of IFNγ in the vicinity of 
CL4 cells and RencaHA cells coming into contact with one and another, increases 
ICAM-1 expression, thus promoting further interactions between LFA-1 and ICAM-1, 
the formation of the synapse, and stabilized binding between these cell types. In 
contrast to signals mediated by through CD28 ligation, the signals associated with 
LFA-1-ICAM-1 interactions appear to be essential for antitumor specific CD8+ T cells 
to overcome the inhibitory effects of PGE2, and generate mature CTL. When 
expression ICAM-1 on RencaHA cells is high (Supplementary Fig. S1C), the 
increased affinity of LFA-1 for ICAM-1 serves to maintain the contact between CL4 
and RencaHA cell, enabling the formation of a stable synapse to be formed between 
the two cell types. Following synapse formation, the signals provided by both TCR–
KdHA  and LFA-1–ICAM-1 interactions further increase Ca2+ influx, inducing a high 
affinity state of LFA-1 for interaction with ICAM-1. In this situation, the inhibitory 
signals on Ca2+ influx in CL4 cells, induced by PGE2-dependent increases in cAMP 
levels, cannot override the stimulatory signals maintained by stable TCR–Kd/HA and 
LFA-1–ICAM-1 interactions, such that the net result is the expansion of antitumor 
CTL.  
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In conclusion, the data presented in this report support the thesis that overproduction 
of PGE2 by tumor cells that have metastasized to the TDLN favors tumor 
progression in the presence of an otherwise competent immune system by 
preventing productive activation of tumor-specific CTL responses within the TDLN.  
Thus, the use of PGE2-specific inhibitors to reduce or inhibit PGE2 production at the 
tumor site could promote antitumor-specific CTL responses from both naïve and pre-
activated CD8+ T cells. Our data also show that IFNγ-dependent upregulation of 
ICAM-1 expression by tumor cells protects tumor-specific CTLs from the inhibitory 
effect of PGE2, by sustaining CD8+ T-cell activation, proliferation, and induction of 
CTL effector function. Therefore, drugs that can increase the expression of cell-
surface expression of ICAM-1 by tumor cells could provide us with a powerful 
immune-therapeutic tool to counteract the CTL-inhibitory action of tumor-derived 
PGE2,, and ultimately control tumor growth. 
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Figure 1: PGE2 can inhibit or enhance the effector function of naïve CL4 cells, 
primed by RencaHA tumor cells. Naïve, Thy1.1+ CFSE-labeled CL4 cells (1 x 106) 
were cultured (A) with  irradiated RencaHA tumor cells (1 x 105) in the presence or 
absence of different concentrations of PGE2 (RencaHA+CL4)+PGE2 (top panels), or 
with irradiated RencaHA tumor cells (1 x 105); pretreated with different 
concentrations of PGE2 overnight (RencaHA+PGE2)+CL4 (bottom panels),  (B) 
precoated with anti-CD3 (10 µg/ml) alone, or with anti-CD3 plus or minus anti-CD28 
(5µg/ml) in the presence of 10-6 M PGE2. Bars (A), show CL4 T-cell proliferation as 
counts per minutes (cpm) of 3H-thymidine incorporation (left) and the percentage 
change in IFNγ+ CL4 cells (right). (B; left) show CL4 T-cell proliferation as loss of 
CFSE versus IFNγ (top row) as well the number of divided cells (bottom). Numbers 
in the left quadrants show the percentage of CL4 cells that produce IFNγ.  Bars (B; 
right) show IFNγ expression amongst Thy1.1+ CL4 cells with and without PGE2.  
Data are representative four separate experiments. Statistical analyses were carried 
out using one way ANOVA followed by Bonferroni’s test, *P <0.05, ** P <0.01, *** P 
< 0.0001.   
  
27 
 
Figure 2: The presence of PGE2 in the culture is required to inhibit priming of 
both naïve and effector CL4 cells. A, Naïve Thy1.1+ CFSE-labeled CL4 cells (1 x 
106) were cultured with irradiated RencaHA cells (1 x 105) in the absence or 
presence of 10-6 M PGE2 (Primary cultures) for  48 h. Primed CL4 cells (1 x 106) 
were collected from the primary cultures and co-cultured again with 1x105 fresh 
irradiated RencaHA tumor cells in the presence or absence of 10-6M PGE2 for a 
further 72 h (Secondary cultures).  Dot plots show CL4 T-cell proliferation as loss of 
CFSE, together with IFNγ expression amongst Thy1.1+ CL4 cells. Numbers in the 
left quadrants show the percentage of CL4 cells that have proliferated and/or 
produce IFNγ from the total CL4 population acquired. Data are representative of 
three separate experiments. B, 2x106 naïve CL4 cells were also cultured in the 
presence or absence of 10-6M PGE2. CL4 cells were lysed and the levels of 
intracellular cAMP determined by ELISA. Bars show mean expression of cAMP 
amongst CL4 cells expressed as pg/ml. Error bars represent SD.  Statistical 
analyses were carried out using one way ANOVA.  ***P < 0.0001.  Data are 
representative of two separate experiments. 
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Figure 3: IFNγ reverses the inhibition of CTL function caused by PGE2.  1x106 
naïve, Thy1.1+ CFSE-labeled CL4 cells were cultured in 24 well plates with: (A&B) 
irradiated RencaHA or Renca-NT tumor cells (1 x 105), or (C) coated with mAbs to 
CD3 mAb (10 µg/ml) and CD28 (5 µg/ml). Cultures were left untreated (alone) or 
treated with rIFNγ (10 ng/ml) and/or 10-6 M PGE2 for 72 h. CL4 cells were isolated 
from the cultures and analyzed by flow cytometry.  Dot plots show proliferation as 
loss of CFSE amongst CL4 cells gated on Thy1.1 expression versus either (A&C) 
IFNγ or (B) CD69. Numbers show the percentage of CL4 cells that are in the 
quadrant.  Data are representative of two separate experiments. 
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Figure 4.  IFNy is vital during the initial phases of RencaHA-mediated priming 
of naïve CL4 CD8+ T cells. Irradiated RencaHA and Renca-NT tumor cells (1 x 105) 
were cocultured with naïve Thy1.1+ CFSE-labeled CL4 cells (1 x 106) in the 
presence or absence of 10-6 M PGE2.  Cultures were left untreated (no rIFNγ), or 
treated with 10 ng/ml of rIFNγ at the beginning (0 h), and after 2 h or 40 h of the 
culture.  At 72 h, CL4 cells were isolated from cultures and stained for intracellular 
IFNγ.  Dot plots are gated on Thy1.1+ CL4 cells, and numbers above indicate the 
percentage of IFNγ+ CL4 cells. Data are representative four independent 
experiments. 
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Figure 5: CL4 CD8+ T-cell activation with anti-CD3 along with either rICAM-1 or 
anti-CD28. Naïve, Thy1.1+ CFSE-labeled CL4 cells (2 × 104) were cultured with 
either PBS or combinations of anti-CD3 (10 µg/ml), anti-CD28 (5 µg/ml) and rICAM-1 
(3 µg/ml) as shown. A: Bars show CL4 proliferation as counts per minute (cmp) from 
3H-thymidine incorporation at 48 and 72 h for each condition and error bars 
represent standard deviation (SD). Data are collected from three independent 
experiments. Statistical analyses were carried out using one way ANOVA followed 
by Bonferroni’s test ***P < 0.0001. B: Histograms (bottom) show proliferation as loss 
of CFSE labeling, and dot plots (upper) show expression of CD44 and CD62L and 
IFNγ. Numbers in each dot plot show percentage of proliferated cells expressing 
each marker.  Data is representative of two separate experiments. 
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Figure 6: The effect of rICAM-1 on CL4 CD8+ T-cell proliferation in the presence 
of PGE2. Naïve, Thy1.1+ CL4 cells (2 × 104) were cultured in 96 well plates: (A) with 
either PBS or combinations of anti-CD3 (10 µg/ml), anti-CD28 (5 µg/ml) and rICAM-1 
(3 µg/ml), in the presence or absence of 10-6 M PGE2 as shown, or (B) with different 
concentrations of rICAM-1 plus 1 ×1 04 irradiated RencaHA cells or Renca-NT cells 
and 1 × 104 purified naïve CL4 CD8+ T in the presence or absence of 10-6 M PGE2.  
Bars show mean proliferation of CL4 cells at 48h for each condition as counts per 
minute (cpm) of 3H-thymidine incorporation, and error bars represent standard 
deviation (SD).  Statistical analyses were carried out using one way ANOVA followed 
by Bonferroni’s test, *P < 0.05, ***P < 0.0001.  Data is representative of four 
separate experiments. 
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Figure 7: Overexpression of ICAM-1 by PGE2-expressing tumor cells restores 
CL4 proliferation in vitro and inhibits tumor growth in vivo.  
A: Renca-HA/T3 and Renca-HA/T3/ICAM-1 cells were cultured in the presence or 
absence of 10ng/ml of IFNγ for 48 h, then stained for ICAM-1. Histograms show anti-
ICAM-1 mAb staining of non-treated cultures (solid) and the IFNγ-treated cells 
(dashed). Filled line represents isotype control mAb staining of non-IFNγ-treated 
cells. B: Irradiated Renca-HA/T3 and Renca-HA/T3/ICAM-1 cells were also cultured 
with 1 x 104 naïve CL4 cells at a ratio of 1:1.  Bars show mean proliferation of CL4 
cells at 48 h as counts per minute (cpm) of 3H-thymidine incorporation. Error bars 
represent standard deviation (SD).  Statistical analyses were carried out using one 
way ANOVA followed by Bonferroni’s test, ***P < 0.0001.  Data is representative of 
four separate experiments.  (C) Groups of 6 to 8 week old BALB/c mice, were 
injected s.c. with either 1 × 106 RencaHA/T3 (•) or with RencaHA/T3/ICAM-1 (×) cells 
and tumor size plotted for each mouse (where n=5 for each group), and (D) mean 
size and SD for each group.  Statistical analyses were carried out using one way 
ANOVA followed by Bonferroni’s test, ***P < 0.0001  
 
